Corporate Overview

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.

Our lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. We believe that our preliminary Phase 1/2 data from our ongoing clinical trial provide us with clinical proof of concept for our HER2 Boltbody ISAC approach.

Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1.


June 4, 2021

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021Read More

June 2, 2021

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development CollaborationRead More

May 13, 2021

Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business HighlightsRead More

View All News Releases


July 6, 2021

NASDAQ Opening Bell Read More

June 4, 2021

2021 American Society of Clinical Oncology (ASCO) Annual Meeting Read More

April 15, 2021 at 10:15 AM EDT

20th Annual Needham Virtual Healthcare Conference Read More

View All Upcoming Events